Ann Surg Oncol (2018) 25:1980–1985 https://doi.org/10.1245/s10434-018-6484-8 OR IGINAL ARTIC L E – COLORECTAL CANCER High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal Blake D. Babcock, MD, Mayada A. Aljehani, DrPH, Brice Jabo, MD, MPH, Audrey H. Choi, MD, John W. Morgan, DrPH, MPH, Matthew J. Selleck, DO, Fabrizio Luca, MD, Elizabeth Raskin, MD, Mark E. Reeves, MD, PhD, Carlos A. Garberoglio, MD, Sharon S. Lum, MD, and Maheswari Senthil, MD Loma Linda University Cancer Center, Loma Linda, CA ABSTRACT 95% CI 0.11–0.61), and T4/LVI (HR 0.16, 95% CI Introduction. Adjuvant chemotherapy is recommended in 0.04–0.61). patients with stage II colon cancer with high-risk features Conclusions. Not all high-risk features have similar (HRF). However, there is no quantiﬁcation of the amount adverse effects on OS. T4 tumors and their combination of risk conferred by each HRF or the overall survival (OS) with other HRF achieve the most survival beneﬁt with beneﬁt gained by chemotherapy based on the risk factor. adjuvant therapy. Type and number of high-risk features Objective. To assess survival beneﬁts associated with should be taken into consideration when recommending adjuvant chemotherapy among stage II colon cancer adjuvant chemotherapy in stage II colon cancer. patients having
Annals of Surgical Oncology – Springer Journals
Published: Apr 19, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera